@article{24602af689b346a1b431a58eac20277b,
title = "Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia: Updates from the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse",
author = "Braun, {Theodore P.} and Druker, {Brian J.}",
note = "Funding Information: receiving funding from the Howard Hughes Medical Institute; grants from the National Cancer Institute; personal fees from Aileron Therapeutics, Therapy Architects, Amgen, Aptose Biosciences, Iterion Therapeutics, Blueprint Medicines, the Burroughs Wellcome Fund, Cepheid, GRAIL, Enliven Therapeutics, the Novartis CML molecular monitoring steering committee, the RUNX1 Research Program, VBL Therapeutics, Vincera Pharma, Vivid Biosciences, Celgene, Gilead Sciences, and ICON; and additional support from Enliven Therapeutics, Novartis, Bristol Myers",
year = "2021",
month = jan,
doi = "10.1001/jamaoncol.2020.5772",
language = "English (US)",
volume = "7",
pages = "50--51",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "1",
}